Skip to main content
. 2019 May 7;20(9):2251. doi: 10.3390/ijms20092251

Figure 6.

Figure 6

Paw withdrawal thresholds and latencies are increased after intrathecal administration of SUR1 agonists. Administration of the SUR1 agonist diazoxide (A), the Kir6.2/SUR1 agonist NN-414 (D) or the Kir6.2/SUR2 agonist levcromakalim (E) significantly increased paw withdrawal thresholds compared to vehicle (G) (10 μL, hindpaw; * p < 0.05, repeated measures ANOVA, F (6, 56) = 32.94, * p < 0.05, CI diazoxide = −0.7470 to −0.4126, CI NN414 = −0.999 to −0.1607, CI levcromakalim = −3.363 to −1.969). Error bars: SEM; n = 5–10/group.